IV
IVEVF.US Inventiva S.A
- Market cap
- USD 760M
- P/E
- -
- P/B
- 11.62x
- ROE
- -838.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is IVEVF.US undervalued?
Graham numberThe Graham number of Inventiva S.A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Inventiva S.A fundamental analysis
No fundamental analysis for Inventiva S.A yet.
Inventiva S.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharido…
Full company profileInventiva S.A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Inventiva S.A annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.45M | 6.52M | 3.20M | 7.00M | 372K | 4.19M | 12.2M | 17.5M | 14.7M | 4.48M | 97.7K |
| Gross Profit | 7.96M | 5.28M | 2.23M | 7.00M | 372K | 3.18M | 12.2M | 17.5M | 9.20M | 1.57M | -5.11M |
| Operating Income | -13.0M | -20.9M | -33.3M | -30.3M | -29.7M | -52.1M | -57.1M | -103M | -97.6M | -133M | -299M |
| EBITDA | -10.4M | -21.5M | -32.1M | -28.6M | -27.8M | -48.2M | -55.4M | -102M | -92.4M | -133M | -297M |
| Net Income | -7.05M | -17.2M | -33.6M | -30.2M | -33.6M | -49.6M | -54.3M | -110M | -184M | -354M | -494M |
| EPS | -0.45 | -1.11 | -1.64 | -1.28 | -0.99 | -1.27 | -1.31 | -2.43 | -3.08 | -1.90 | -1.81 |
| Balance Sheet | |||||||||||
| Total Assets | 48.9M | 74.4M | 79.8M | 57.0M | 139M | 122M | 116M | 69.6M | 119M | 250M | 251M |
| Total Liabilities | 13.1M | 10.4M | 18.2M | 15.6M | 27.7M | 33.1M | 70.5M | 102M | 226M | 278M | 192M |
| Shareholders' Equity | 35.7M | 64.0M | 61.6M | 41.4M | 111M | 88.9M | 45.5M | -32.0M | -107M | -28.5M | 58.9M |
| Cash & Short-term Investments | 24.9M | 59.1M | 56.7M | 35.8M | 113M | 95.4M | 87.8M | 27.0M | 96.6M | 231M | 166M |
| Total Debt | 628K | 482K | 2.20M | 2.10M | 13.3M | 10.1M | 34.5M | 37.5M | 54.3M | 59.9M | 139M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -14.9M | -17.0M | -34.2M | -28.4M | -30.6M | -47.6M | -44.9M | -81.6M | -85.9M | -105M | -218M |
| Capital Expenditure | 228K | 428K | 549K | 136K | 292K | 534K | 561K | 540K | 333K | 247K | 713K |
| Free Cash Flow | -15.1M | -17.4M | -34.8M | -28.5M | -30.9M | -48.2M | -45.5M | -82.2M | -86.3M | -105M | -218M |
| Ratios | |||||||||||
| ROE | -19.7% | -26.9% | -54.6% | -73.0% | -30.2% | -55.9% | -119.3% | - | - | - | -838.9% |
| ROA | -14.4% | -23.2% | -42.1% | -53.1% | -24.2% | -40.7% | -46.8% | -158.7% | -154.8% | -141.9% | -197.0% |
| Net Profit Margin | -74.6% | -264.2% | -1,051.5% | -431.9% | -9,037.4% | -1,183.5% | -445.6% | -631.8% | -1,251.1% | -7,899.6% | -506,054.8% |
| Debt to Equity | 0.02x | 0.01x | 0.04x | 0.05x | 0.12x | 0.11x | 0.76x | - | - | - | 2.36x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Inventiva S.A dividends
Inventiva S.A has not paid dividends in the last 9 fiscal years.
Who owns Inventiva S.A
- Insiders 12.52%
- Institutions 49.18%
- Public & others 38.31%
- Shares outstanding 239M
- Free float 180M
Inventiva S.A company profile
- Company name
- Inventiva S.A
- Ticker
- IVEVF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 87
- Fiscal year end
- December
- Address
- 50 rue de Dijon, Daix, France, 21121
- Phone
- 33 3 80 44 75 00
- Website
- inventivapharma.com
About Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Inventiva S.A management
10- Mr. Andrew ObenshainChief Executive Officer · born 1974
- Dr. Pierre Broqua Ph.D.Co-Founder · born 1962
- Mr. Jean VolatierExecutive VP Finance & Corporate Social Responsibility · born 1965
- Dr. Martine Zimmermann Pharm.D.Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs · born 1969
- Mr. Jason A. Campagna M.D., Ph.D.President of Research & Development and Chief Medical Officer · born 1966
- Mr. Axel-Sven MalkomesChief Financial Officer · born 1967
- Mr. Christopher Benecchi M.B.A.Chief Operating Officer · born 1972
- Ms. Jennifer NavaChief Information Officer
- Ms. Susan ColesChief Legal Officer · born 1966
- Ms. Pamela HerbsterChief People Officer